The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Insights into a double-hit ultra-high-risk myeloma subgroup analysis from the RADAR trial
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses a subanalysis from the RADAR trial of ultra-high-risk patients with multiple myeloma, noting that additional genetic abnormalities, high LDH, and higher disease stage significantly impact progression-free survival. Dr Ramasamy highlights that a subset of patients in this group may do poorly with current quadruplet-based induction, consolidation, and doublet maintenance, and suggests that alternative immunotherapeutic approaches may be needed to improve clinical outcomes. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
RADAR trial in the high-risk arm that’s being presented at this meeting is specifically looking at ultra-high-risk patients. So these are patients who have two high-risk abnormalities. And the question we are asking in this sub-analysis is, within this cohort of patients who have two high-risk abnormalities, are they patients who do worse? So we looked at a number of features, which included genetic abnormalities and all the baseline clinical features...
RADAR trial in the high-risk arm that’s being presented at this meeting is specifically looking at ultra-high-risk patients. So these are patients who have two high-risk abnormalities. And the question we are asking in this sub-analysis is, within this cohort of patients who have two high-risk abnormalities, are they patients who do worse? So we looked at a number of features, which included genetic abnormalities and all the baseline clinical features. And the features that are really standing out is having additional genetic abnormalities over the two high-risk abnormalities and having a high LDH and having a higher disease stage appears to impact them significantly from a progression-free survival perspective. So what does this really mean? Our early review of the data suggests that there may be a subset of patients within this ultra-high-risk who could perform even poorly with the current quadruplet-based induction and quadruplet consolidation and doublet maintenance. We’re going to expand this analysis to include up to 125 patients. Currently, we’re presenting data on 70 patients and that will give us a robust analysis which will help tease out these patients who may require alternative immunotherapeutic approaches to improve their clinical outcomes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
